Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $6,017 | 1 | 56.3% |
| Unspecified | $3,200 | 1 | 30.0% |
| Consulting Fee | $1,260 | 2 | 11.8% |
| Food and Beverage | $206.16 | 3 | 1.9% |
Payments by Type
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Incyte Corporation | $6,345 | 3 | $0 (2024) |
| PFIZER INC. | $3,200 | 1 | $0 (2022) |
| Avita Medical Americas, Llc | $1,000 | 1 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $118.20 | 1 | $0 (2023) |
| Galderma Laboratories, L.P. | $20.23 | 1 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,260 | 2 | Avita Medical Americas, Llc ($1,000) |
| 2023 | $185.93 | 2 | Novartis Pharmaceuticals Corporation ($118.20) |
| 2022 | $3,200 | 1 | PFIZER INC. ($3,200) |
| 2021 | $6,017 | 1 | Incyte Corporation ($6,017) |
| 2018 | $20.23 | 1 | Galderma Laboratories, L.P. ($20.23) |
All Payment Transactions
7 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 03/22/2024 | Incyte Corporation | — | Consulting Fee | Cash or cash equivalent | $260.00 | General |
| 03/21/2024 | Avita Medical Americas, Llc | Recell (Device) | Consulting Fee | Cash or cash equivalent | $1,000.00 | General |
| Category: Wound Care | ||||||
| 11/28/2023 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $118.20 | General |
| Category: Dermatology | ||||||
| 07/05/2023 | Incyte Corporation | — | Food and Beverage | Cash or cash equivalent | $67.73 | General |
| 10/20/2022 | PFIZER INC. | — | — | In-kind items and services | $3,200.00 | Research |
| Study: RITLECITINIB CLINICAL PUBLICATION PROGRAM | ||||||
| 10/01/2021 | Incyte Corporation | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $6,017.00 | General |
| 04/27/2018 | Galderma Laboratories, L.P. | EPIDUO FORTE (Drug) | Food and Beverage | In-kind items and services | $20.23 | General |
| Category: ACNE | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| RITLECITINIB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $3,200 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 188 | 244 | $27,470 | $13,650 |
| 2022 | 6 | 204 | 256 | $28,521 | $15,784 |
| 2021 | 9 | 319 | 413 | $39,812 | $22,216 |
| 2020 | 8 | 227 | 260 | $23,765 | $11,516 |
All Medicare Procedures & Services
29 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 81 | 115 | $13,310 | $7,557 | 56.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 28 | 28 | $4,284 | $2,516 | 58.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 29 | 32 | $2,272 | $1,419 | 62.5% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 21 | 21 | $2,062 | $846.19 | 41.0% |
| 11900 | Injection into skin growth, 1-7 growths | Office | 2023 | 14 | 31 | $3,162 | $746.90 | 23.6% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2023 | 15 | 17 | $2,380 | $564.07 | 23.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 89 | 119 | $13,065 | $8,349 | 63.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 28 | 28 | $4,172 | $2,465 | 59.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 33 | 39 | $2,839 | $1,869 | 65.8% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 24 | 24 | $2,193 | $1,465 | 66.8% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2022 | 19 | 20 | $3,600 | $1,039 | 28.9% |
| 11900 | Injection into skin growth, 1-7 growths | Office | 2022 | 11 | 26 | $2,652 | $597.27 | 22.5% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 104 | 141 | $15,660 | $10,223 | 65.3% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 35 | 35 | $5,187 | $3,376 | 65.1% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 58 | 61 | $4,401 | $3,255 | 74.0% |
| 99203 | New patient outpatient visit, total time 30-44 minutes | Office | 2021 | 37 | 37 | $3,337 | $2,233 | 66.9% |
| 17110 | Destruction of up to 14 skin growths | Office | 2021 | 26 | 30 | $5,400 | $1,390 | 25.7% |
| 17000 | Destruction of skin growth | Office | 2021 | 17 | 19 | $2,660 | $769.51 | 28.9% |
| 99202 | New patient outpatient visit, total time 15-29 minutes | Office | 2021 | 15 | 15 | $981.00 | $553.46 | 56.4% |
| 11102 | Tangential biopsy of single skin lesion | Office | 2021 | 13 | 13 | $1,690 | $312.60 | 18.5% |
| 17003 | Destruction of 2-14 skin growths | Office | 2021 | 14 | 62 | $496.00 | $103.65 | 20.9% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 83 | 104 | $9,272 | $5,728 | 61.8% |
| 99202 | New patient office or other outpatient visit, typically 20 minutes | Office | 2020 | 45 | 45 | $2,646 | $1,617 | 61.1% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 29 | 33 | $1,907 | $1,220 | 64.0% |
| 99203 | New patient office or other outpatient visit, typically 30 minutes | Office | 2020 | 16 | 16 | $1,444 | $894.12 | 61.9% |
About Dr. Richard Huggins, M.D
Dr. Richard Huggins, M.D is a Dermatology healthcare provider based in Detroit, Michigan. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/02/2008. The National Provider Identifier (NPI) number assigned to this provider is 1619136934.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Richard Huggins, M.D has received a total of $10,683 in payments from pharmaceutical and medical device companies, with $1,260 received in 2024. These payments were reported across 7 transactions from 5 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($6,017).
As a Medicare-enrolled provider, Huggins has provided services to 938 Medicare beneficiaries, totaling 1,173 services with total Medicare billing of $63,165. Data is available for 4 years (2020–2023), covering 29 distinct procedure/service records.
Practice Information
- Specialty Dermatology
- Location Detroit, MI
- Active Since 06/02/2008
- Last Updated 07/10/2012
- Taxonomy Code 207N00000X
- Entity Type Individual
- NPI Number 1619136934
Products in Payments
- Recell (Device) $1,000
- COSENTYX (Drug) $118.20
- EPIDUO FORTE (Drug) $20.23
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Dermatology Doctors in Detroit
David Ozog, M.d, M.D
Dermatology — Payments: $28,730
Karen Heidelberg, M.d, M.D
Dermatology — Payments: $11,115
Dr. Tina Pickett Baisden, Md, MD
Dermatology — Payments: $8,752
Dr. Emily Keimig, M.d, M.D
Dermatology — Payments: $7,939
Dr. Snehal Desai, M.d, M.D
Dermatology — Payments: $7,297
Leah Cardwell, M.d, M.D
Dermatology — Payments: $5,220